TAS-119
- Generic Name
- TAS-119
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05489731
- Locations
- 🇨🇳
Zhangli, Guangdong, China
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Vitrac Therapeutics, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT05374538
- Locations
- 🇺🇸
New York University Langone Health Perlmutter Cancer Cancer, New York, New York, United States
🇺🇸University of California Davis, Sacramento, California, United States
🇺🇸Emory University Winship Cancer Center, Atlanta, Georgia, United States
An Investigation of TAS-119 Monotherapy
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02448589
- Locations
- 🇺🇸
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
🇮🇹San Raffaele Hospital, Milano, Italy
🇪🇸START MADRID-FJD, Hospital Fundación Jiménez DÃaz, Madrid, Spain
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02134067
- Locations
- 🇺🇸
University of Colorado Hospital Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Washington University School of Medicine Division of Oncology Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.